Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
How to buy Humana stock in Canada | $458.64
Own Humana shares in just a few minutes.
Humana is a healthcare plans business based in the US. Humana stocks (HUM.US) are listed on the NYSE and all prices are listed in US Dollars. Its last market close was $454.5 – a decrease of 0.47% over the previous week. Humana employs 48,700 staff and has a trailing 12-month revenue of around $80.5 billion.
How to buy shares in Humana
- Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
- Open your brokerage account. Complete an application with your details.
- Confirm your payment details. Fund your account.
- Research the stock. Find the stock by name or ticker symbol – HUM – and research it before deciding if it's a good investment for you.
- Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
- Check in on your investment. Optimize your portfolio by tracking your stock.
Is it a good time to buy Humana stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
What's in this guide?
- Can I buy shares in Humana?
- Has coronavirus impacted Humana shares?
- Humana shares summary
- Compare share dealing platforms
- Is Humana stock a buy or sell?
- Humana performance over time
- Can I short Humana shares?
- Is Humana suitable for ethical investing?
- Are Humana shares over-valued?
- Humana's financials
- How volatile are Humana shares?
- Does Humana pay a dividend?
- Have Humana shares ever split?
- Other common questions
How has Coronavirus impacted Humana's stock price?
Since the stock market crash in March caused by coronavirus, Humana's stock price has had significant positive movement.
Its last market close was $458.64, which is 19.40% up on its pre-crash value of $369.67 and 120.24% up on the lowest point reached during the March crash when the stocks fell as low as $208.25.
If you had bought $1,000 worth of Humana stocks at the start of February 2020, those stocks would have been worth $643.29 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth $1,375.92.
Humana stock priceUse our graph to track the performance of HUM stocks over time.
Humana shares at a glance
|Latest market close||$458.64|
|52-week range||$368.38 - $473.85|
|50-day moving average||$412.29|
|200-day moving average||$429.97|
|Wall St. target price||$486.46|
|Dividend yield||$2.65 (0.58%)|
|Earnings per share (TTM)||$18.91|
Compare online stock trading platforms
Note: The dollar amounts in the table below are in Canadian dollars.
Humana price performance over time
|1 week (2021-10-21)||-0.47%|
|1 month (2021-09-28)||16.11%|
|3 months (2021-07-28)||4.04%|
|6 months (2021-04-28)||4.56%|
|1 year (2020-10-28)||10.98%|
|2 years (2019-10-28)||58.50%|
|3 years (2018-10-26)||44.11%|
|5 years (2016-10-28)||168.12%|
Is Humana under- or over-valued?
Valuing Humana stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Humana's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Humana's P/E ratio
Humana's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 24x. In other words, Humana shares trade at around 24x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
Humana's PEG ratio
Humana's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 1.3537. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Humana's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Humana's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $4.2 billion.
The EBITDA is a measure of a Humana's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||$80.5 billion|
|Operating margin TTM||4.89%|
|Gross profit TTM||$15.5 billion|
|Return on assets TTM||6.43%|
|Return on equity TTM||16.97%|
|Market capitalisation||$59.4 billion|
TTM: trailing 12 months
Shorting Humana shares
There are currently 1.8 million Humana shares held short by investors – that's known as Humana's "short interest". This figure is 7.6% down from 1.9 million last month.
There are a few different ways that this level of interest in shorting Humana shares can be evaluated.
Humana's "short interest ratio" (SIR)
Humana's "short interest ratio" (SIR) is the quantity of Humana shares currently shorted divided by the average quantity of Humana shares traded daily (recently around 739972.08333333). Humana's SIR currently stands at 2.4. In other words for every 100,000 Humana shares traded daily on the market, roughly 2400 shares are currently held short.
However Humana's short interest can also be evaluated against the total number of Humana shares, or, against the total number of tradable Humana shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Humana's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 Humana shares in existence, roughly 10 shares are currently held short) or 0.0138% of the tradable shares (for every 100,000 tradable Humana shares, roughly 14 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Humana.
Humana's environmental, social and governance track record
Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like Humana.
When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.
Humana's total ESG risk score
Total ESG risk: 25.71
Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and Humana's overall score of 25.71 (as at 01/01/2019) is pretty good – landing it in it in the 33rd percentile of companies rated in the same sector.
ESG scores are increasingly used to estimate the level of risk a company like Humana is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).
Humana's environmental score
Environmental score: 2.6/100
Humana's environmental score of 2.6 puts it squarely in the 3rd percentile of companies rated in the same sector. This could suggest that Humana is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.
Humana's social score
Social score: 18.54/100
Humana's social score of 18.54 puts it squarely in the 3rd percentile of companies rated in the same sector. This could suggest that Humana is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.
Humana's governance score
Governance score: 5.07/100
Humana's governance score puts it squarely in the 3rd percentile of companies rated in the same sector. That could suggest that Humana is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.
Humana's controversy score
Controversy score: 2/5
ESG scores also evaluate any incidences of controversy that a company has been involved in. Humana scored a 2 out of 5 for controversy – the second-highest score possible, reflecting that Humana has, for the most part, managed to keep its nose clean.
Humana share dividends
Dividend payout ratio: 17.76% of net profits
Recently Humana has paid out, on average, around 17.76% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 0.61% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), Humana shareholders could enjoy a 0.61% return on their shares, in the form of dividend payments. In Humana's case, that would currently equate to about $2.65 per share.
While Humana's payout ratio might seem low, this can signify that Humana is investing more in its future growth.
Humana's most recent dividend payout was on 29 October 2021. The latest dividend was paid out to all shareholders who bought their shares by 29 September 2021 (the "ex-dividend date").
Have Humana's shares ever split?
Humana's shares were split on a 3:2 basis on 1 August 1991. So if you had owned 2 shares the day before before the split, the next day you'd have owned 3 shares. This wouldn't directly have changed the overall worth of your Humana shares – just the quantity. However, indirectly, the new 33.3% lower share price could have impacted the market appetite for Humana shares which in turn could have impacted Humana's share price.
Humana share price volatility
Over the last 12 months, Humana's shares have ranged in value from as little as $368.3751 up to $473.8507. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Humana's is 0.8878. This would suggest that Humana's shares are less volatile than average (for this exchange).
Humana Inc. , together with its subsidiaries, operates as a health and well-being company in the United States. It operates through Retail, Group and Specialty, and Healthcare Services segments. The company offers medical and supplemental benefit plans to individuals. It also has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits. In addition, the company provides commercial fully-insured medical and specialty health insurance benefits comprising dental, vision, and other supplemental health benefits; and administrative services only products to individuals and employer groups, as well as military services, such as TRICARE T2017 East Region contract. Further, it offers pharmacy solutions, provider services, predictive modeling and informatics services, and clinical care services, such as home health and other services to its health plan members, as well as to third parties.
Stocks similar to Humana
Frequently asked questions
Humana in the news
Thinking about buying stock in Gilead Sciences, Avadel Pharmaceuticals, Humana, Tesla, or Ford Motor?
Humana Healthy Horizons Launches Louisiana Statewide Mobile Clinic Initiative with Ochsner Health
Humana Expands Medicare Advantage Network to Include Northeast Georgia Health System, Longstreet Clinic and Others Across Region
More on investing
Stock trading doesn’t have to be expensive. Using Finder’s proprietary algorithm, we’ve identified the best cheap Canadian and US stocks to buy now.Read more…
Steps to owning and managing Cue Health stocks, with 24-hour and historical pricing before you buy.Read more…
Steps to owning and managing ARBK stock, with 24-hour and historical pricing before you buy.Read more…
More guides on Finder
How to buy ARK 21Shares Bitcoin ETF (ARKB) stock in Canada when it goes public
Everything we know about the ARK 21Shares Bitcoin ETF IPO, plus information on how to buy in.
How to buy ARK 21Shares Bitcoin Futures Strategy ETF (ARKA) stock in Canada when it goes public
Everything we know about the ARK 21Shares Bitcoin Futures Strategy ETF IPO, plus information on how to buy in.
How to buy FaZe Clan (FAZE) stock in Canada when it goes public
Everything we know about the FaZe Clan IPO, plus information on how to buy in.
How to buy Valkyrie Bitcoin Strategy ETF (BTF) stock in Canada
Steps to owning and managing Valkyrie Bitcoin Strategy ETF units.
How to buy VanEck Bitcoin Strategy ETF (XBTF) stock in Canada when it goes public
Everything we know about the VanEck Bitcoin Strategy ETF IPO, plus information on how to buy in.
How to buy Trump Media and Technology Group stock in Canada when it goes public
Everything we know about the Trump Media and Technology Group IPO, plus information on how to buy in.
How to buy ProShares Bitcoin Strategy ETF (BITO) stock in Canada
Steps to owning and managing ProShares Bitcoin Strategy ETF units.
How to buy AirSculpt Technologies (AIRS) stock in Canada when it goes public
Everything we know about the AirSculpt Technologies IPO, plus information on how to buy in.
How to buy Candela Medical (CDLA) stock in Canada when it goes public
Everything we know about the Candela Medical IPO, plus information on how to buy in.
How to buy Ensemble Health Partners (ENSB) stock in Canada when it goes public
Everything we know about the Ensemble Health Partners IPO, plus information on how to buy in.